Therapeutic Focus
Innovative Therapeutic Options for Life Threatening Diseases
Since our founding in 1994, ViroPharma has focused its attention on bringing new product opportunities forward for some of society’s great unmet medical needs. We hope that our efforts will result in improved treatment alternatives for patients suffering from diseases with few, if any, treatment alternatives.
Today, our current focus is to develop these important, new products for physician specialists supporting patients with serious diseases for which there are significant unmet needs. Our goal is to bring new therapeutic alternatives to patients with serious or potentially life threatening diseases whose needs are not being met by their current therapeutic options, or for whom there are no existing treatments. Our work is focused in areas including ultra orphan diseases, niche infectious diseases, gastroenterology and transplant medicine.
With Cinryze™ (C1 Esterase Inhibitor [human)], a drug indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), we are providing HAE patients with an important drug targeting the underlying cause of HAE attacks, a deficiency in a protein in the body called C1 inhibitor. The Cinryze PI can be found here.
In addition, with Vancocin®, a potent oral antibiotic used to treat two significant bacterial infections of the lower digestive tract, antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , we provide an important antibiotic to our targeted physician specialists, internists and gastroenterologists in hospital settings. The Vancocin PI can be viewed here. Beyond Vancocin, our intent is to develop novel therapeutics to prevent recurrent C. difficile disease.
Further, physicians focused in transplant medicine must contend with the repercussions of the suppressed immune systems of patients undergoing stem cell (bone marrow) or solid organ transplant, including organ failure and rejection, a variety of opportunistic infections, and other transplant complications. One of the most significant pathogens contributing to morbidity and mortality in patients undergoing stem cell or solid organ transplant is cytomegalovirus. Maribavir, a specific antiviral medicine, targets cytomegalovirus which may cause a deadly disease in patients undergoing stem cell and organ transplant
Thanks to the success of Cinryze and Vancocin, we are today in the enviable position of investigating new products that aim to save and improve the lives of patients suffering from deadly diseases.